跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 778 条关于
“OXM”
全部
778
临床试验
231
药物
498
机构
16
资讯
33
去年
Entera Bio and OPKO Health Announce Positive PK/PD Results for Oral Oxyntomodulin for Obesity and Metabolic Disorders
去年
Entera Bio Announces Positive Updates on Oral Peptide Programs and Q3 2024 Financial Results
7个月前
Opko Health and Entera Bio Expand Partnership to Develop First Oral Long-Acting PTH Therapy for Hypoparathyroidism
2年前
Innovent's Mazdutide Achieves Phase 3 Success in Chinese Obesity Trial, Paving Way for First GLP-1R/GCGR Dual Agonist Approval
2年前
NeuroBo Pharmaceuticals Completes Enrollment in Phase 1 Trial of DA-1726 for Obesity
去年
NeuroBo's DA-1726 Shows Positive Safety and Tolerability in Phase 1 Obesity Trial
8个月前
MetaVia's DA-1726 Demonstrates 9.1% Weight Loss and Significant Metabolic Benefits in Phase 1b Obesity Trial
去年
MetaVia's Novel Dual Receptor Agonist Shows Promising 6.3% Weight Loss in Phase 1 Obesity Trial
上个月
Bill Ackman Commits $260 Million to Establish Brain Research Institute in Manhattan Following Daughter's Hemorrhage
去年
Innovent to Present Phase 3 Results of Dual GLP-1/Glucagon Receptor Agonist Mazdutide at ADA 2025
第 1 页,共 4 页
上一页
下一页